Genetics: Immune Response to Cancer Treatment

Mohammad Asif

doi:10.36648/ipgmbr.21.5.37

Genetics: Immune Response to Cancer Treatment

Mohammad Asif^*

Center for Bio-Technology, Institute of Science & Technology, JNTU University, India

Corresponding Author:: Mohammad Asif
Center for Bio-Technology, Institute of Science & Technology, JNTU University, India
E-mail: asifm326@gmail.com

Received Date: January 5, 2021; Accepted Date: January 22, 2021; Published Date: January 29, 2021

Citation: Asif M(2021) Genetics: Immune Response to Cancer Treatment. Genet Mol Biol Res Vol No: 5 Iss No: 1:37

Copyright: © 2021 Asif M. This is an open-access article distributed under the terms of the Creative Commons Attributions License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Genetics and Molecular Biology Research

Keywords Immune; Cancer

Commentary A new study has found that inherited genetic variation plays a role in who is likely to benefit from checkpoint inhibitors, which release the immune system’s brakes so it can attack cancer. The study also points to potential new targets that could help even more patients unleash their immune system’s natural power to fight off malignant cells.

The next step is to use the data to formulate “polygenic” approaches—taking a large number of genes into account to predict which cancer patients will benefit from current therapies, and developing new drugs for those who will not.